Treatment is frequently required before, during, and after pregnancy in women with rheumatic diseases. It is essential that maternal disease be well controlled to ensure the best possible outcome for mother and child. The physician has multiple responsibilities to monitor not only the interactions between the underlying maternal disease and the outcome of pregnancy, but also the impact of the medications on both patients. The limited experience with cytotoxic medications prior to or during pregnancy in women with rheumatic diseases will be addressed in this article.
ASJC Scopus subject areas